BRAF and non-small cell lung carcinoma: One study reported that the incidence of baseline BMs in patients with BRAF-mutant metastatic NSCLC was significantly lower for class I mutations (9%) than for class II (29%; P = 0.011) or class III (31%; P = 0.007) mutations33.